Professor, Medicine, University of Chicago Div of the Bio Sci The Pritzker SOM
Oncology
Dr. Andrzej J. Jakubowiak, MD
|
|
Give Review
Andrzej Jakubowiak is an expert in the field of Oncology. He over the years received 1 awards: "Regional Top Doctor". Dr. Andrzej J. Jakubowiak is also published. He has 54 publications published. The lastest publication: "Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro.' He accepts all Medicare patients.
Publications
- Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
- Targeting deubiquitinase activity with a novel small molecule inhibitor as therapy for B-cell malignancies.
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma.
- Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple Myeloma.
- Evolution of carfilzomib dose and schedule in patients with multiple Myeloma: A historical overview.
- Current strategies for treatment of relapsed/refractory multiple Myeloma.
- A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory Myeloma.
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple Myeloma: a randomized phase 2 study.
- Treatment outcomes in patients with relapsed and refractory multiple Myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
- Current approaches to the initial treatment of symptomatic multiple Myeloma.
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple Myeloma: a Phase I Multiple Myeloma Research Consortium study.
- Monoclonal antibodies in the treatment of multiple Myeloma.
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple Myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
- Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple Myeloma.
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple Myeloma.
- Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed Myeloma.
- Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untre...
- Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I...
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple Myeloma patients.
- Cladribine underdosing in hairy-cell Leukemia: a cause for apparent response failure.
- Extended follow-up of a phase 3 trial in relapsed multiple Myeloma: final time-to-event results of the APEX trial.
- A practical guide to achieving and maintaining the best response to lenalidomide in multiple Myeloma: roundtable proceedings.
- Genomic complexity identifies patients with aggressive chronic lymphocytic Leukemia.
- The research mission in Myeloma.
- Pulsatile GnRH stimulation increases steady-state mRNA levels for FSHbeta, LHbeta, and alpha subunits in superfused pituitary cell cultures.
- Effects of cyclic AMP and phorbol ester on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment culture.
- Effect of cadmium chloride on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment cultures--a new model for toxicological investigation...
- Effects of recombinant human inhibin and testosterone on gonadotropin secretion and subunit mRNA in superfused male rat pituitary cell cultures stimulated with pulsati...
- Regulation of transepithelial electrical resistance in two-compartment Sertoli cell cultures: in vitro model of the blood-testis barrier.
- Action kinetics of inhibin in superfused pituitary cells depend on gonadotropin-releasing hormone treatment.
- Kinetics of inhibin secretion in static and superfused Sertoli cell cultures in response to follicle-stimulating hormone.
- Vectorial secretion of inhibin by immature rat Sertoli cells in vitro: reexamination of previous results.
- Similar effects of inhibin and cycloheximide on gonadotropin release in superfused pituitary cell cultures.
- Evaluation of HLA expression on gametogenic cells isolated from human testis.
- Effect of germ cells on vectorial secretion of androgen binding protein and transferrin by immature rat Sertoli cells in vitro.
- Transferrin secretion in response to different modes of FSH stimulation and cycloheximide in superfused Sertoli cell cultures.
- Reproductive functions in the adult male rats after prolonged intraventricular administration of corticotropin-releasing factor (CRF).
- Study of the dynamics of Sertoli cell secretions in a new superfusion, two-compartment culture system.
- Stimulatory effect of Sertoli cell secretory products on testosterone secretion by purified Leydig cells in primary culture.
- Culture of rat Sertoli cells isolated with a modified procedure. Morphological identification of cell population and cell reactivity.
- Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro.
- Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro.
- The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
- Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO Leukemia-associated fusion protein.
- Molecular biology of Leukemia.
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple Myeloma.
- Superior overall survival of patients with Myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin...
- Peripheral neuropathy during bortezomib treatment of multiple Myeloma: a review of recent studies.
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple Myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
- Initial genome sequencing and analysis of multiple Myeloma.
- Phase 1 study of marizomib in relapsed or relapsed and refractory multiple Myeloma; NPI 0052 101 Part 1.
Schools
Med Academic
University Tex Med School
Meml Sloan Kettering Canc Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Memorial Sloan-Kettering Cancer Center -
University of Texas Health Science Center -
University of Medical Science Poznan
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1134205081 | |
| NPPES Provider LastName | JAKUBOWIAK | |
| NPPES Provider FirstName | ANDRZEJ | |
| NPPES Provider ZIPCode | 606371447 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 165.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134205081 |
| Last Name Of The Provider | JAKUBOWIAK |
| First Name Of The Provider | ANDRZEJ |
| View All |
Similar Doctors
|
|
Dr. Victoria M. Villaflor, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey C. Cilley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John L. Showel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hidayatullah G. Munshi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Andrea Karoff, LCSW |